Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 1/20 | 0.77 |
| ▸ | DRD2 | P14416 | 6/20 | 0.67 |
| ▸ | DRD3 | P35462 | 6/20 | 0.67 |
| ▸ | DRD4 | P21917 | 4/20 | 0.67 |
| ▸ | HTR1A | P08908 | 4/20 | 0.67 |
| ▸ | HTR7 | P34969 | 4/20 | 0.67 |
| ▸ | DRD1 | P21728 | 1/20 | 0.67 |
| ▸ | DRD5 | P21918 | 1/20 | 0.67 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3313069 | 1.00 | CHRM3 (0.77) | CHRM3DRD2DRD3DRD4HTR1A | |
| SCHEMBL3312525 | 1.00 | CHRM3 (0.77) | CHRM3DRD2DRD3DRD4HTR1A | |
| SCHEMBL8891132 | 0.87 | CHRM3 (1.00) | CHRM3DRD2DRD3HTR1AHTR7 | |
| SCHEMBL28966833 | 0.84 | DRD2 (0.68) | DRD2DRD3DRD4HTR1AHTR7 | |
| SCHEMBL30201151 | 0.84 | DRD2 (0.68) | DRD2DRD3DRD4HTR1AHTR7 | |
| 5-Oh-Dpat SCHEMBL279021 | 0.80 | DRD2 (1.00) | DRD2DRD3DRD4HTR1AHTR7 | |
| 5-Oh-Dpat SCHEMBL5705486 | 0.80 | DRD2 (1.00) | DRD2DRD3DRD4HTR1AHTR7 | |
| 5-Oh-Dpat SCHEMBL17446178 | 0.80 | DRD2 (1.00) | DRD2DRD3DRD4HTR1AHTR7 | |
| 5-Oh-Dpat SCHEMBL29420186 | 0.80 | DRD2 (1.00) | DRD2DRD3DRD4HTR1AHTR7 | |
| 5-Oh-Dpat SCHEMBL30201073 | 0.80 | DRD2 (1.00) | DRD2DRD3DRD4HTR1AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348358-A1 | Serotonin Receptor Modulators | UNITED STATES GOVERNMENT | 2023-11-02 | — | — | US | disclosed |
| US-20230348358-A1 | Serotonin Receptor Modulators | UNITED STATES GOVERNMENT | 2023-11-02 | — | — | US | disclosed |
| US-8097641-B2 | Heterocyclyl substituted tetrahydronaphthalene derivatives as 5-HT7 receptor ligands | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-01-17 | — | — | US | disclosed |
| US-20100197717-A1 | COMBINATION OF A 5HT7 RECEPTOR LIGAND AND AN OPIOID RECEPTOR LIGAND | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-08-05 | — | — | US | disclosed |
| US-20100035936-A1 | HETEROCYCLYL SUBSTITUTED TETRAHYDRONAPHTHALENE DERIVATIVES AS 5-HT7 RECEPTOR LIGANDS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-02-11 | — | — | US | disclosed |
| EP-2148674-A1 | COMBINATION OF A 5HT7 RECEPTOR LIGAND AND AN OPIOID RECEPTOR LIGAND | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2010-02-03 | — | — | EP | disclosed |
| EP-2114893-A1 | HETEROCYCLYL SUBSTITUTED TETRAHYDRONAPHTHALENE DERIVATIVES AS 5-HT7 RECEPTOR LIGANDS | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008145335-A1 | COMBINATION OF A 5HT7 RECEPTOR LIGAND AND AN OPIOID RECEPTOR LIGAND | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-12-04 | — | — | WO | disclosed |
| EP-1997493-A1 | Combination of a 5-HT7 receptor ligand and an opioid receptor ligand | Laboratorios del Dr. Esteve S.A. (ES) | 2008-12-03 | — | — | EP | disclosed |
| WO-2008095689-A1 | HETEROCYCLYL SUBSTITUTED TETRAHYDRONAPHTHALENE DERIVATIVES AS 5-HT7 RECEPTOR LIGANDS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-08-14 | — | — | WO | disclosed |
| EP-1956006-A1 | Heterocyclyl-substituted-tetrahydro-naphthalen derivatives as 5-HT7 receptor ligands | Laboratorios del Dr. Esteve S.A. (ES) | 2008-08-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197717-A1 | COMBINATION OF A 5HT7 RECEPTOR LIGAND AND AN OPIOID RECEPTOR LIGAND | OPRL1, OPRM1, OPRK1 | CHRM3 57/4885DRD2 184/4885DRD3 240/4885 |
| US-20100035936-A1 | HETEROCYCLYL SUBSTITUTED TETRAHYDRONAPHTHALENE DERIVATIVES AS 5-HT7 RECEPTOR LIGANDS | HTR7, HTR2C, HTR6 | CHRM3 340/4885DRD2 264/4885DRD3 370/4885 |
| US-20230348358-A1 | Serotonin Receptor Modulators | HTR7, HTR1A, HTR5A | CHRM3 2079/4885DRD2 298/4885DRD3 834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.